|

The Spotlight Roundup-The First-Ever Female Founded Psychedelic Company

BySarah Abelsohn

July 7, 2021- This week’s Psychedelic Business News top stories include:
– Mydecine Innovations Group Makes A Huge Mushroom Discovery
– Field Trip Health Prepares for the Nasdaq
– Psychedelic Research Makes It’s Way To Texas
– We Introduce You To The First-Ever Female-Founded Psychedelic Biotech Company, Aphrodite

AND MORE!

Read The Latest News: https://bit.ly/2TGUyrM

FOLLOW US:
—————————————-
đź“° SIGN UP FOR OUR NEWSLETTER:
https://bit.ly/3vZMsYJ

📲 SOCIAL:
Facebook: https://www.facebook.com/PsychedelicS…
Instagram: https://www.instagram.com/psycspotlight/
Twitter: https://twitter.com/PsycSpotlight
LinkedIn: https://www.linkedin.com/company/psyc…

#psychedelics​​​ #texas #mushrooms

source

Similar Posts

  • This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI, FTPRF, ATAI & CYBN]

    Listen, Videos

    In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some News on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin (CYBN) & Fieldtrip Health (FTPRF).

    I covered some breaking news on MindMed yesterday in our impromptu episode on the MindMed stock being added to the EFSE so that mindmed news is not in this episode.

    We will cover the latest developments in the field writ large.
    This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

    Timestamps:
    0:00 – Intro
    0:43 – Australian federal government funds psychedelic research to treat mental illnesses
    2:19 – Rhode Island wants to decriminalize all drugs
    3:54 – New York Bill to decriminalize psilocybin mushrooms
    6:34 – MindMed stock updates ( mmed, mmedf, mmq )
    8:17 – Compass Pathways stock news (cmps)
    8:49 – Atai Life Sciences news
    12:37 – Fieldtrip Health stock news ( ftprf, ftrp)
    15:04 – Numinus Wellness stock news ( NUMI, LKYSF)
    16:16 – Cybin stock news ( cybn, clxpf)
    18:18 General psychedelics discussion

    So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

  • Interview with James Lanthier, CEO of Mindset Pharma

    Interviews, Listen, Podcasts

    In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.